Search Results - "Volm, Manfred"

Prediction of Cancer Drug Resistance and Implications for Personalized Medicine by Volm, Manfred, Efferth, Thomas

“…Drug resistance still impedes successful cancer chemotherapy. A major goal of early concepts in individualized therapy was to develop in vitro tests to predict…”
Get full text

Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs by EFFERTH, Thomas, BADIREENATH KONKIMALLA, V, WANG, Yi-Fen, SAUERBREY, Axel, MEINHARDT, Silke, ZINTL, Felix, MATTERN, Jürgen, VOLM, Manfred

“…Purpose: Drug resistance is a major obstacle in cancer chemotherapy. Although the statistical probability of therapeutic success is known for larger patient…”
Get full text

Molecular modes of action of artesunate in tumor cell lines by Efferth, Thomas, Sauerbrey, Axel, Olbrich, Armin, Gebhart, Erich, Rauch, Pia, Weber, H Oliver, Hengstler, Jan G, Halatsch, Marc-Eric, Volm, Manfred, Tew, Kenneth D, Ross, Douglas D, Funk, Jens Oliver

“…A profound cytotoxic action of the antimalarial, artesunate (ART), was identified against 55 cancer cell lines of the U.S. National Cancer Institute (NCI). The…”
Get more information

Multiple resistance to carcinogens and xenobiotics: P-glycoproteins as universal detoxifiers by Efferth, Thomas, Volm, Manfred

“…The detoxification of toxic substances is of general relevance in all biological systems. The plethora of exogenous xenobiotic compounds and endogenous toxic…”
Get full text

Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer by Volm, Manfred, Koomägi, Reet, Mattern, Juergen

“…Tumor specimens from 109 patients with previously untreated squamous cell lung carcinomas were analyzed immunohistologically for the expression of vascular…”
Get full text

Glutathione-related Enzymes Contribute to Resistance of Tumor Cells and Low Toxicity in Normal Organs to Artesunate by Efferth, Thomas, Volm, Manfred

“…The anti-malarial artesunate (ART) also inhibits the growth of cancer cells. The active moiety is an endoperoxide bridge whose cleavage generates reactive…”
Get full text

Overcoming of P-glycoprotein-mediated multidrug resistance of tumors in vivo by drug combinations by Saeed, Mohamed, Zeino, Maen, Kadioglu, Onat, Volm, Manfred, Efferth, Thomas

“…Inhibition of P-glycoprotein represents an attractive possibility to modulate resistance of cancer cells to anticancer drugs. One major strategy to overcome…”
Get full text

Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance by Koomägi, Reet, Volm, Manfred

“…In order to examine whether or not the expression of the apoptosis‐related receptor Fas (CD‐95/APO‐1) and its ligand (FasL) has relevance for patient survival,…”
Get full text

Imbalance of Cell Proliferation and Apoptosis During Progression of Lung Carcinomas by MATTERN, Jürgen, VOLM, Manfred

“…To evaluate the relationship between cell proliferation and apoptosis during progression of lung carcinomas, immunohistochemistry for proliferating cell…”
Get full text

Expression Profile of Genes in Non-Small Cell Lung Carcinomas from Long-Term Surviving Patients by VOLM, Manfred, KOOMÄGI, Reet, MATTERN, Jürgen, EFFERTH, Thomas

“…Purpose: Non-small cell lung cancer (NSCLC) is usually associated with a poor prognosis. Some patients survive their disease, and the underlying molecular…”
Get full text

Vascular Endothelial Growth Factor in Newly Diagnosed and Recurrent Childhood Acute Lymphoblastic Leukemia as Measured by Real-Time Quantitative Polymerase Chain Reaction by KOOMAGI, Reet, ZINTL, Felix, SAUERBREY, Axel, VOLM, Manfred

“…Purpose: Overexpression of vascular endothelial growth factor (VEGF) is associated with increased angiogenesis, growth, and metastasis in solid tumors, but to…”
Get full text

Angiostatin Expression in Non-Small Cell Lung Cancer by VOLM, M, MATTERN, J, KOOMÄGI, R

“…Angiostatin, a potent inhibitor of angiogenesis, tumor growth, and metastasis, was examined in a panel of human lung cancer cell lines with Western blot…”
Get full text

Biological Characterization of Subgroups of Squamous Cell Lung Carcinomas by MATTERN, J, KOOMÄGI, R, VOLM, M

“…Recently, Pezzella et al. (Am. J. Pathol., 1997, 151: 1417–1423, 1997) reported on a subgroup of non-small cell lung carcinomas that had no morphological…”
Get full text

Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy? by Lippert, Theodor Hermann, Ruoff, Hans-Jörg, Volm, Manfred

“…The frequent resistance of malignant tumors to chemotherapy documents the fact that numerous patients are uselessly traumatized by highly toxic drugs…”
Get more information

Current status of methods to assess cancer drug resistance by Lippert, Theodor H, Ruoff, Hans-Jörg, Volm, Manfred

“…Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, resistance being either preexisting (intrinsic resistance) or induced by…”
Get full text

Prediction of Drug Sensitivity and Resistance of Cancer by Protein Expression Profiling by MANFRED VOLM, REET KOOMAGI, THOMAS EFFERTH

“…Although the statistical probability of therapeutic success is known for larger groups of cancer patients, the clinical response to chemotherapy of the…”
Get full text

Protein Expression Profiles Indicative for Drug Resistance of Kidney Carcinoma by THOMAS EFFERTH MANFRED VOLM

“…The purpose of this investigation was to evaluate whether different protein patterns exist between drug-sensitive and drug-resistant kidney carcinomas. As a…”
Get full text

Characteristics of long-term survivors of untreated lung cancer by Mattern, Jürgen, Koomägi, Reet, Volm, Manfred

“…Non-small cell lung cancer (NSCLC) is a malignant tumor with poor prognosis. Although the prognostic variables determining short-term survival have been well…”
Get full text

Clinical implications of cyclins, cyclin‐dependent kinases, RB and E2F1 in squamous‐cell lung carcinoma by Volm, Manfred, Koomägi, Reet, Rittgen, Werner

“…In the search for new risk factors at the molecular and cellular levels, clinical data [lymph‐node involvement (LN) and stage] were used and 104 squamous‐cell…”
Get full text

CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients by Salnikov, Alexei V., Gladkich, Jury, Moldenhauer, Gerhard, Volm, Manfred, Mattern, Jürgen, Herr, Ingrid

“…Despite advances in anticancer treatment, lung cancer still has poor prognosis. Recently, a cancer stem cell (CSC) hypothesis has emerged describing a small…”
Get full text